In an individual participant data meta-analysis of 3 placebo-controlled trials (14 574 people with CKD), finerenone cut kidney failure or ≥57% eGFR decline (22·3 vs 28·8 per 1000 patient-years; HR 0·76) and HF hospitalisation or CV death (HR 0·80); more hyperkalaemia.
Meta-analysisn = 14,574
Neuen et al. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)